Loïc Ysebaert

Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO)

Abstract Recently venetoclax (Ven) monotherapy showed promising efficacy for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM), a population with significant medical unmet need. We report the efficacy and safety of Ven associated or not with anti-CD20 therapy, in a rea...